We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't giving FDA the resources to make the case that they should be prescribed, we're going to be…

I know this is an issue that doesn't necessarily fit natural to Congress to be funding physician and provider education, but we're talking about next year reports suggesting that 8 of the top 10 drugs on the market are going to be…

Biologics have provided major advances in the treatment of cancer, rheumatologic disease, and other conditions.

These reductions will result in significant savings to the healthcare system and patients as the biosimilar market matures.

This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insurance companies place higher cost sharing burdens on biologics.

I hope that we can talk about that today.

Thank you, Mr. Chairman.

We talked about the certainty that the industry needs to start populating the field with more biosimilars.

I think the consensus here is that there is a vacuum.

The United States, I think, is uniquely qualified to provide that type of international leadership.

I agree with everything you have said, and I just want to make sure that we have a sober understanding of, amongst those problems, which ones we can solve and which ones we cannot.

It is a sound strategy, but how is it working?

I sort of still feel like there is this leftover hubris in which we think that we are the most important player in the region.

I think that there is a potentially really significantly high cost to the United States compared to what I would suggest is a potentially really low positive reward.

I still am not clear whether we are pressing the right levers internally to get the kind of political reconciliation necessary.

I say to Senator Durbin, I come from Connecticut, one of the Thirteen Original Colonies. We are proud of our role as part of the foundation, the fabric of America, and our State's motto is ``He who transplants sustains.'' This Nation's…

I am back to the floor a second time to speak very briefly in favor of the nuclear agreement with Iran. I don't clearly understand why we are here again. When I was sworn into the House, I remember that one of the things people told me was…

I feel the same cycle playing out again in which the crutch of the American military... is just sort of lulling them into a sense of political complacency that is dangerous.

We have to deal with the root causes, but we also have to deal with the humanitarian crisis and help save lives.

Our effectiveness in combating the ISIL threat cannot be measured solely by the number of sorties flown.

I did not see it while I was there.

I come to the floor to speak to the nuclear agreement with Iran. First, having just come back from the region after having spent Sunday morning in one of the biggest refugee camps inside Syria--where 80,000, more than half of them children…

one thing we all agree on is that Iran cannot obtain a nuclear weapon. That has been the foundation of American policy. For a long time, it has been at the root of these negotiations. That has been our guidepost as a body. It certainly has…

I ask unanimous consent for my State Department fellow, Tovan McDaniel, to be granted floor privileges for the remainder of this work period. The PRESIDING OFFICER. Without objection, it is so ordered. ____________________

Almost without exception schools are making decisions about programs based on what's best for students.